Valneva SE: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vivalis SA Issues FY 2013 Revenue Guidance
Vivalis SA announced that it expects its revenue to increase for full year 2013 compared to full year 2012 as a result of its commercial strategy. The Company reported full year 2012 revenue of EUR 3.43 million.
Latest Developments for Valneva SE
- Valneva SE confirms FY 2014 outlook guidance
- Valneva SE announces first ever marketing approval in Europe for vaccine produced in EB66 cell line
- Valneva SE announces first marketing authorization for human vaccine produced in EB66 cell line
- Valneva SE announces approval and launch in South America of second veterinary vaccine produced in EB66 cell line
Latest Key Developments in Biotechnology
- Rich Pharmaceuticals Inc announces submission of IND application to FDA for treatment of acute myelocytic leukemia and myelodysplastic syndrome
- Celator Pharmaceuticals Inc prices $12.9 mln public offering of common stock and warrants to purchase common stock
- TAKARA BIO INC amends consolidated mid-year outlook for FY 2015
- Erytech Pharma SA successfully raises 30 mln euro for expanding its therapeutic indications in oncology and accelerating its clinical developments
- Share this
- Digg this